Drug Profile
Research programme: antioxidants - Abiogen Pharma
Alternative Names: Antioxidants - Abiogen Pharma; CNS disorders therapeutics - Abiogen Pharma; CRAM 1-2Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Abiogen Pharma
- Class
- Mechanism of Action Antioxidants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported CNS disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in CNS-disorders in Italy
- 19 Jul 2010 Preclinical development is ongoing in Italy
- 18 Mar 2008 Preclinical trials in CNS disorders in Italy (unspecified route)